Hideyuki Otani is a rough at small human cells that can turn into many ties. Back in 2007, the professor from the Graduate College of Medicine at Tokyo’s Keio University received an award that ranked him among the world’s top stem cell researchers. Now living up to its price. Otani’s group, along with colleague Masaya Nakamura and a team of researchers, will conduct the world’s first clinical trial of a spinal cord injury therapy to help paralyzed people walk again.
Finally, this week, the Ministry of Health approved the testing of Okano’s stem cell treatment on four patients. To get underway in the summer. Each of the paraplegic subjects is injected with 200 million neural stem cells, derived from the true all-comers, induced pluripotent stem (iPS) cells, into the severed nerve connection. In addition, test subjects receive drugs that suppress the immune response. After all, the body is not supposed to fight the small foreign cells, but to let them do their work, the growth of new nerve tracts.
At affchen it already went
The rough hope is that what the cell cocktail has already achieved in monkeys will be repeated in humans: that paraplegics will be able to walk again. The test subjects will be followed by the researchers over the course of a year in order to record not only progress but also possible side effects such as cancer.